Prostate cancer genetic alterations in hispanic men

Abstract Background Differences in DNA alterations in prostate cancer among White, Black, and Asian men have been widely described. This is the first description of the frequency of DNA alterations in primary and metastatic prostate cancer samples of self‐reported Hispanic men. Methods We utilized targeted next‐generation sequencing tumor genomic profiles from prostate cancer tissues that underwent clinical sequencing at academic centers (GENIE 11th). We decided to restrict our analysis to the samples from Memorial Sloan Kettering Cancer Center as it was by far the main contributor of Hispanic samples. The numbers of men by self‐reported ethnicity and racial categories were analyzed via Fisher's exact test between Hispanic‐White versus non‐Hispanic White. Results and Limitations Our cohort consisted of 1412 primary and 818 metastatic adenocarcinomas. In primary adenocarcinomas, TMPRSS2 and ERG gene alterations were less common in non‐Hispanic White men than Hispanic White (31.86% vs. 51.28%, p = 0.0007, odds ratio [OR] = 0.44 [0.27–0.72] and 25.34% vs. 42.31%, p = 0.002, OR = 0.46 [0.28–0.76]). In metastatic tumors, KRAS and CCNE1 alterations were less prevalent in non‐Hispanic White men (1.03% vs. 7.50%, p = 0.014, OR = 0.13 [0.03, 0.78] and 1.29% vs. 10.00%, p = 0.003, OR = 0.12 [0.03, 0.54]). No significant differences were found in actionable alterations and androgen receptor mutations between the groups. Due to the lack of clinical characteristics and genetic ancestry in this dataset, correlation with these could not be explored. Conclusion DNA alteration frequencies in primary and metastatic prostate cancer tumors differ among Hispanic‐White and non‐Hispanic White men. Notably, we found no significant differences in the prevalence of actionable genetic alterations between the groups, suggesting that a significant number of Hispanic men could benefit from the development of targeted therapies.